AI Market Mood: Stock Dashboard
ZBIO
Fundamental
Company: Zenas Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -4.23
Insider Own: 75.62%
Shs Outstand: 42.09M
Perf Week: 12.24%
Market Cap: 704.51M
Forward P/E: -
EPS next Y: -4.16
Insider Trans: 0.08%
Shs Float: 10.22M
Perf Month: 21.85%
Enterprise Value: 432.24M
PEG: -
EPS next Q: -1.21
Inst Own: 35.90%
Short Float: 51.13%
Perf Quarter: 59.79%
Income: -177.01M
P/S: 46.97
EPS this Y: 63.45%
Inst Trans: 1.32%
Short Ratio: 31.13
Perf Half Y: 140.03%
Sales: 15.00M
P/B: 2.94
EPS next Y Percentage: 4.28%
ROA: -71.80%
Short Interest: 5.23M
Perf YTD: 104.27%
Book/sh: 5.69
P/C: 2.58
EPS next 5Y: 30.18%
ROE: -88.40%
52W High: 26.25 -36.27%
Perf Year: -
Cash/sh: 6.49
P/FCF: -
EPS past 3/5Y: -9.85% -
ROIC: -73.80%
52W Low: 5.83 186.96%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: 99.31%
Volatility W: 7.35%
Volatility M: 8.10%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 28.82
EPS Y/Y TTM: -
Oper. Margin: -1260.67%
ATR (14): 1.23
Perf 10Y: -
Dividend Ex-Date: Dec 24, 2019
Quick Ratio: 5.23
Sales Y/Y TTM: -
Profit Margin: -1180.04%
RSI (14): 64.06
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 5.23
EPS Q/Q: -25.86%
SMA20: 5.51%
Beta: -
Target Price: 31.57
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: 29.60%
Rel Volume: 1.91
Prev Close: 16.82
Employees: 130
LT Debt/Eq: 0.00
Earnings: Aug 12 BMO
SMA200: 55.59%
Avg Volume: 167.84K
Price: 16.73
IPO: Sep 13, 2024
Option/Short: Yes / Yes
EPS/Sales Surpr.: -20.42% -100.00%
Trades:
Volume: 133,410
Change: -0.54%
Technical:
Latest News:
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 million valuation in US IPO somewhat bullish
ZBIO
Summary: Zenas BioPharma aims for a valuation of up to $689.7 million in its U.S. IPO, backed by Bristol-Myers Squibb and targeting to raise $211.7 million by offering 11.76 million shares.
Full article2024-09-06T12:28:43Z